Michael Pitzner - Molecular Partners Compliance Counsel
| MOLN Stock | USD 4.87 0.11 2.21% |
Insider
Michael Pitzner is Compliance Counsel of Molecular Partners AG
| Address | Wagistrasse 14, Schlieren, Switzerland, 8952 |
| Phone | 41 44 755 77 00 |
| Web | https://www.molecularpartners.com |
Molecular Partners Management Efficiency
The company has return on total asset (ROA) of (0.1931) % which means that it has lost $0.1931 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3188) %, meaning that it created substantial loss on money invested by shareholders. Molecular Partners' management efficiency ratios could be used to measure how well Molecular Partners manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of October 2024, Return On Tangible Assets is likely to grow to -0.3. In addition to that, Return On Capital Employed is likely to drop to -0.35. At this time, Molecular Partners' Non Currrent Assets Other are very stable compared to the past year. As of the 20th of October 2024, Intangible Assets is likely to grow to about 245.5 K, while Total Assets are likely to drop about 193.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jonathan Ward | 23Andme Holding Co | N/A | |
| Edward Calamai | DiaMedica Therapeutics | N/A | |
| Perry Celentano | Valneva SE ADR | N/A | |
| Darlene Solomon | Agilent Technologies | 65 | |
| Joseph Mara | Vericel Corp Ord | 48 | |
| Anne Wojcicki | 23Andme Holding Co | N/A | |
| Padraig McDonnell | Agilent Technologies | 49 | |
| Allison Ballmer | Agilent Technologies | N/A | |
| Gerald Strohmaier | Valneva SE ADR | N/A | |
| Katharine Knobil | Agilent Technologies | 56 | |
| Laetitia BachelotFontaine | Valneva SE ADR | N/A | |
| Joe Lewcock | Denali Therapeutics | N/A | |
| Wade Walke | 23Andme Holding Co | 58 | |
| Mikael Dolsten | Agilent Technologies | 62 | |
| Marc TessierLavigne | Denali Therapeutics | 64 | |
| Susan Rataj | Agilent Technologies | 63 | |
| Otis Brawley | Agilent Technologies | 61 | |
| Jonathan Siegal | Vericel Corp Ord | N/A | |
| Alexander MD | Denali Therapeutics | 51 | |
| Dominic Cundari | DiaMedica Therapeutics | 73 | |
| Scott CA | DiaMedica Therapeutics | 59 | |
Management Performance
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.19 |
Molecular Partners Leadership Team
Elected by the shareholders, the Molecular Partners' board of directors comprises two types of representatives: Molecular Partners inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Molecular. The board's role is to monitor Molecular Partners' management team and ensure that shareholders' interests are well served. Molecular Partners' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Molecular Partners' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Hendriks, Senior Finance | ||
| Alexander Zurcher, COO Board | ||
| Michael Pitzner, Compliance Counsel | ||
| MD MBA, Interim Officer | ||
| Daniel Steiner, Senior Technology | ||
| Anne DVM, Senior Development | ||
| Thomas Schwerzmann, VP HR | ||
| Michael Stumpp, Executive CoFounder | ||
| Andreas EMBA, Advisor | ||
| Seth Lewis, Communications Relations | ||
| Patrick Amstutz, CEO, CoFounder | ||
| Renate Gloggner, Executive Board | ||
| Pamela Trail, Strategic Consultant |
Molecular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Molecular Partners a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (10.30) % | ||||
| Current Valuation | (9.65 M) | ||||
| Shares Outstanding | 33.19 M | ||||
| Shares Owned By Institutions | 2.59 % | ||||
| Number Of Shares Shorted | 31.15 K | ||||
| Price To Earning | 1.85 X | ||||
| Price To Book | 0.90 X | ||||
| Price To Sales | 21.69 X |
Pair Trading with Molecular Partners
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Molecular Partners position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will appreciate offsetting losses from the drop in the long position's value.Moving together with Molecular Stock
| 0.81 | VALN | Valneva SE ADR | PairCorr |
| 0.82 | DYAI | Dyadic International | PairCorr |
| 0.84 | ERNA | Eterna Therapeutics | PairCorr |
Moving against Molecular Stock
| 0.82 | GILD | Gilead Sciences | PairCorr |
| 0.66 | GNFT | Genfit | PairCorr |
| 0.64 | BMY | Bristol Myers Squibb | PairCorr |
| 0.62 | INBX | Inhibrx Symbol Change | PairCorr |
| 0.47 | WVE | Wave Life Sciences | PairCorr |
The ability to find closely correlated positions to Molecular Partners could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Molecular Partners when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Molecular Partners - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Molecular Partners AG to buy it.
The correlation of Molecular Partners is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Molecular Partners moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Molecular Partners moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Molecular Partners can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.02) | Revenue Per Share 0.239 | Quarterly Revenue Growth 2.737 | Return On Assets (0.19) | Return On Equity (0.32) |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.